Irish contract research player Ulysses Neuroscience is providing the global pharma sector with ground-breaking research services.
Irish contract research organisation (CRO) Ulysses Neuroscience has successfully raised €500,000 in investment from Enterprise Ireland and private investment company Growing Capital.
Since its foundation in June 2019, Ulysses Neuroscience is providing the patient community and the global pharmaceutical industry with ground-breaking research services to advance knowledge and therapies of psychiatric diseases and rare neurological disorders.
“We have been able to breakthrough the CRO market and are helping a range of industries to bring their new therapies into clinical trials and subsequently onto the market”
Ulysses Neurosciences’ recent strategic move to the newly built Pioneer Group life sciences facilities in Cherrywood in Dublin has initiated a transformative phase of growth for the company, opening doors to a new industry network.
The company is currently hiring for preclinical and clinical neuroscience positions in the psychedelic, psychiatric and rare neurodevelopmental research space.
With offices and labs Located at the Pioneer Group life sciences facilities in Cherrywood and Trinity College Dublin, Ulysses neuroscience has 15 employees and a portfolio of several clients worldwide with a strong presence in the US market.
Bringing therapies to market faster
“This raise of €500,000 in investment is an important milestone allowing us to expand our patient-centric and translational neuroscience research platforms,” said Dr Massimiliano Bianchi, CEO of Ulysses Neuroscience.
“With a portfolio of globally based pharma clients and an annual revenue of over €1m, we have been able to breakthrough the CRO market and are helping a range of industries to bring their new therapies into clinical trials and subsequently onto the market.
“The relocation to the Pioneer Group facilities in Cherrywood was driven by our vision to be the vanguard CRO in neuroscience drug discovery. Our new laboratories are fully operational and dedicated to perform and progress the company biomarker and cell cultures operations,” Bianchi added.
“We are delighted to support Ulysses Neuroscience in their pursuit to combat psychiatric diseases and rare neurological disorders, contributing to advancements in the pharmaceutical industry,” Gianni Matera, founder, Growing Capital said.
“We’ve been truly impressed by Ulysses’ commitment to actively engaging patients in the research and drug development journey, ensuring their voices are not only heard but valued at every stage. It’s gratifying to see this approach being acknowledged by the global pharmaceutical industry.”
The Irish company is also based onsite at Trinity College Dublin where a dedicated team of expert preclinical scientists are currently developing an electroencephalographic assay destined to be the next breakthrough model for exploring the use of psychedelics for the treatment of depression and the use of gene-therapy for curing rare neurodevelopmental diseases.
“Enterprise Ireland is delighted to support Ulysses Neuroscience and the important work they are doing in bringing ground-breaking treatment in the field of neurodevelopment to the market for the benefit of the patient community right across the world,” said Leo Clancy, CEO, Enterprise Ireland.
“With this funding the company plans to scale its operations, and to continue to expand its market reach across the US, EU and Asian markets with a particular focus on expanding their clinical biomarker services. We look forward to working with the Ulysses Neuroscience team to realise their global ambition.”
Main image at top: Gianni Matera, Founder, Growing Capital, Dr. Massimiliano Bianchi, CEO, Ulysses Neuroscience, Cepta Duffy, HPSU Lifesciences Department Manager, Enterprise Ireland, Leo Clancy, CEO, Enterprise Ireland
-
Bank of Ireland is welcoming new customers every day – funding investments, working capital and expansions across multiple sectors. To learn more, click here
